Status:
RECRUITING
Attentional Mechanisms in SCD
Lead Sponsor:
Vanderbilt University Medical Center
Conditions:
Subjective Cognitive Decline
Eligibility:
All Genders
55+ years
Phase:
EARLY_PHASE1
Brief Summary
This study will use an anticholinergic pharmacological probe to examine attention network function in SCD using EEG. The overall hypothesis is that in older adults with SCD, normal cognitive performan...
Detailed Description
Overview: Cognitively normal older adults with and without subjective cognitive decline (SCD) (n = 80) will complete two study visits that will be double blinded and randomized for anticholinergic cha...
Eligibility Criteria
Inclusion
- age ≥ 55
- Montreal Cognitive Assessment (MoCA) \> 25 AND Global Deterioration Scale (GDS) rating \< 3
- Non-smokers
Exclusion
- medical contraindications to the drug challenge
- primary neurological disorder (such as stroke, epilepsy, etc.)
Key Trial Info
Start Date :
March 27 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2028
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06002477
Start Date
March 27 2025
End Date
June 30 2028
Last Update
June 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37212